Literature DB >> 24002497

Challenge and opportunity of targeted lung cancer chemoprevention.

Steven M Dubinett1, Avrum Spira.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24002497     DOI： 10.1200/JCO.2013.51.2400

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

1.  Enhanced antitumor activity of 3-bromopyruvate in combination with rapamycin in vivo and in vitro.

Authors:  Qi Zhang; Jing Pan; Ronald A Lubet; Steven M Komas; Balaraman Kalyanaraman; Yian Wang; Ming You
Journal:  Cancer Prev Res (Phila)       Date:  2015-02-02

2.  Loss of miR125a expression in a model of K-ras-dependent pulmonary premalignancy.

Authors:  Elvira L Liclican; Tonya C Walser; Saswati Hazra; Kostyantyn Krysan; Stacy J Park; Paul C Pagano; Brian K Gardner; Jill E Larsen; John D Minna; Steven M Dubinett
Journal:  Cancer Prev Res (Phila)       Date:  2014-06-09

3.  Effect of weekly or daily dosing regimen of Gefitinib in mouse models of lung cancer.

Authors:  Qi Zhang; Ruichao Li; Xu Chen; Sang Beom Lee; Jing Pan; Donghai Xiong; Jiaqi Hu; Mark Steven Miller; Eva Szabo; Ronald A Lubet; Yian Wang; Ming You
Journal:  Oncotarget       Date:  2017-08-02

4.  ATM/CHK/p53 Pathway Dependent Chemopreventive and Therapeutic Activity on Lung Cancer by Pterostilbene.

Authors:  Hani Lee; Yonghwan Kim; Ji Hye Jeong; Jae-Ha Ryu; Woo-Young Kim
Journal:  PLoS One       Date:  2016-09-09       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.